Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09MLQ
|
|||
| Former ID |
DIB019336
|
|||
| Drug Name |
PMID22153340C20
|
|||
| Synonyms |
GTPL6568; BDBM50360964
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C22H21NO6S
|
|||
| Canonical SMILES |
CC1=CC=C(O1)C2=CC3=C(C=C2)OC4=C3C=CC(=C4)S(=O)(=O)NC(C(C)C)C(=O)O
|
|||
| InChI |
1S/C22H21NO6S/c1-12(2)21(22(24)25)23-30(26,27)15-6-7-16-17-10-14(18-8-4-13(3)28-18)5-9-19(17)29-20(16)11-15/h4-12,21,23H,1-3H3,(H,24,25)/t21-/m0/s1
|
|||
| InChIKey |
LLJREHOWNIBILL-NRFANRHFSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-12 (MMP-12) | Target Info | Inhibitor | [1] |
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| WikiPathways | TGF beta Signaling Pathway | |||
| Degradation of collagen | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorg Med Chem Lett. 2012 Jan 1;22(1):138-43. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6568). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.